Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response

被引：122

作者：

Rosen, Robert H. ^{[2
]}

Gupta, Aditya K. ^{[1
]}

Tyring, Stephen K. ^{[3
]}

机构：

[1] Univ Toronto, Dept Med, Sch Med, Div Dermatol, Toronto, ON, Canada

[2] So Suburbs Dermatol, Sydney, NSW, Australia

[3] Univ Texas Hlth Sci Ctr Houston, Dept Dermatol, Sch Med, Houston, TX USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2012年 / 66卷 / 03期

关键词：

actinic keratosis; ingenol mebutate gel; mechanism of action; neutrophil; neutrophil-mediated antibody-dependent cellular cytotoxicity; protein kinase C; rapid lesion necrosis; 2.5-PERCENT HYALURONAN GEL; IMIQUIMOD 5-PERCENT CREAM; VEHICLE-CONTROLLED TRIALS; BASAL-CELL CARCINOMA; DOUBLE-BLIND; PARALLEL-GROUP; INGENOL-3-ANGELATE; NEUTROPHILS; EUPHORBIACEAE; FLUOROURACIL;

D O I：

10.1016/j.jaad.2010.12.038

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Current topical agents for field therapy of actinic keratoses have single mechanisms of action and must be applied for weeks. Ingenol mebutate gel, a novel drug for field therapy of actinic keratoses, appears to have a dual mechanism of action: (1) rapid lesion necrosis and (2) specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Because of the rapid destruction of actinic keratosis lesions after application of ingenol mebutate gel, treatment is necessary for only 2 or 3 days. The subsequent immune-mediated response targets any residual dysplastic epidermal cells. This dual mechanism of action should provide efficacy equivalent to that of current topical agents with a substantially shorter treatment period. (J Am Acad Dermatol 2012;66:486-93.)

引用

页码：486 / 493

页数：8

共 35 条

[1]

ADOLF W, 1983, J SCI SOC THAILAND, V9, P81

[2]

ANDERSON L, 2007, AM AC DERM 2007 SUMM

[3] Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis [J].

Anderson, Lawrence ;

Schmieder, George J. ;

Werschler, W. Philip ;

Tschen, Eduardo H. ;

Ling, Mark R. ;

Stough, Dow B. ;

Katsamas, Janelle .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (06) :934-943

[4]

Berman B, 2009, 2009 S BEACH S FEB 1

[5] Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate [J].

Challacombe, Jodie M. ;

Suhrbier, Andreas ;

Parsons, Peter G. ;

Jones, Brad ;

Hampson, Peter ;

Kavanagh, Dean ;

Rainger, G. Ed ;

Morris, Melanie ;

Lord, Janet M. ;

Le, Thuy T. T. ;

Hoang-Le, Diem ;

Ogbourne, Steven M. .

JOURNAL OF IMMUNOLOGY, 2006, 177 (11) :8123-8132

[6] The intriguing role of polymorphonuclear neutrophils in antitumor reactions [J].

Di Carlo, E ;

Forni, G ;

Lollini, P ;

Colombo, MP ;

Modesti, A ;

Musiani, P .

BLOOD, 2001, 97 (02) :339-345

[7]

Fariba Iraji, 2006, Indian J Dermatol Venereol Leprol, V72, P346

[8]

Freeman M, 2008, SUMM AC 08 AM AC DER

[9]

Giorgi C, 2008, CURR MOL MED, V8, P119

[10]

Green A C, 1988, Australas J Dermatol, V29, P127, DOI 10.1111/j.1440-0960.1988.tb00383.x

← 1 2 3 4 →